Business
PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms
LayerBio’s OcuRing™-K program and broader ocular platform strengthen PRF’s healthcare growth strategy DeepSolar advances from acquisition to early commercial
About this update from Prf Technologies Ltd.
[{"type":"text","content":"LayerBio’s OcuRing™-K program and broader ocular platform strengthen PRF’s healthcare growth strategy DeepSolar advances from acquisition to early commercial deployment TEL AVIV, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) today provided a business update for the year ended December 31, 2025, in conjunction with the filing of its Annual Report on Form 20-F. 2025 and early 2026 Highlights Completed the strategic acquisition of DeepSolar, expanding PRF into AI-driven solar analytics and establishing a second high-growth operating platform.Completed a majority investment in LayerBio, adding OcuRing™-K, a patented drop-less, sustained-release ocular therapy platform targeting post-cataract pain and inflammation control.Advanced OcuRing™-K through development planning and IND-supporting activities, with preclinical and Phase I safety data supporting continued progression toward later-stage development.Reported additional R&D progress supporting the broader potential of LayerBio’s sustained-release ocular platform, including confirmation that the platform can accommodate multiple drug entities, reinforcing its long-term applicability across ophthalmic indications.Expanded DeepSolar’s commercial and product footprint through the launch of Smart TDD, acceptance into the NVIDIA Connect Program, filing of PRF’s first DeepSolar patent application, a SaaS agreement with Shikun & Binui Energy for a 71 MW solar project in Romania, and a first commercial due diligence engagement with EDF Power Solutions Israel.Maintained a disciplined capital structure while continuing to invest in both business units, ending 2025 with approximately $4.1 million in cash, cash equivalents, short-term deposits and restricted cash, and positive working capital of approximately $2.0 million. Dr. Ehud Geller, Executive Chairman of PRF Technologies, commented, “2025 was a transformational year for PRF as we repositioned the Company into a diversified innovation platform spanning healthcare and renewable-energy analytics. In healthcare, we significantly strengthened our pipeline and strategic focus through our majority investment in LayerBio and the continued advancement of OcuRing™-K, which we believe has the potential to address a large unmet need in cataract surgery through a truly drop-less, sustained-r...